Similar articles

• All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.

  Kim Y, Jeung HK, Cheong JW, Song J, Bae SH, Lee JI, Min YH. Kim Y, et al. Yonsei Med J. 2020 Sep;61(9):762-773. doi: 10.3349/ymj.2020.61.9.762. Yonsei Med J. 2020. PMID: 32882760 Free PMC article.
• Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.

  Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, Wang X, Carlos BR, Yilmaz M, Kadia T, Andreeff M, Ravandi F, Konopleva M, Kantarjian HM, DiNardo CD. Venugopal S, et al. Blood Cancer J. 2022 Jan 25;12(1):10. doi: 10.1038/s41408-021-00604-2. Blood Cancer J. 2022. PMID: 35078972 Free PMC article. Clinical Trial.
• IDH2 inhibition in AML: Finally progress?

  Stein EM. Stein EM. Best Pract Res Clin Haematol. 2015 Jun-Sep;28(2-3):112-5. doi: 10.1016/j.beha.2015.10.016. Epub 2015 Oct 19. Best Pract Res Clin Haematol. 2015. PMID: 26590767 Review.
• The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.

  Nassereddine S, Lap CJ, Haroun F, Tabbara I. Nassereddine S, et al. Ann Hematol. 2017 Dec;96(12):1983-1991. doi: 10.1007/s00277-017-3161-0. Epub 2017 Oct 31. Ann Hematol. 2017. PMID: 29090344 Review.
• Positive First Trial of Enasidenib for AML.

  [No authors listed] [No authors listed] Cancer Discov. 2017 Aug;7(8):OF1. doi: 10.1158/2159-8290.CD-NB2017-098. Epub 2017 Jun 28. Cancer Discov. 2017. PMID: 28659444 Clinical Trial.